HC Wainwright cut shares of Cassava Sciences (NASDAQ:SAVA – Free Report) from a buy rating to a neutral rating in a report released on Monday morning, MarketBeat.com reports.
Cassava Sciences Stock Performance
Shares of NASDAQ:SAVA opened at $12.14 on Monday. Cassava Sciences has a 52-week low of $8.79 and a 52-week high of $32.10. The company has a market capitalization of $582.43 million, a P/E ratio of -5.59 and a beta of -0.50. The company has a 50-day simple moving average of $20.66 and a 200 day simple moving average of $22.01.
Cassava Sciences (NASDAQ:SAVA – Get Free Report) last issued its earnings results on Friday, May 10th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.90). As a group, equities analysts forecast that Cassava Sciences will post -1.86 earnings per share for the current year.
Institutional Investors Weigh In On Cassava Sciences
About Cassava Sciences
Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
Featured Articles
- Five stocks we like better than Cassava Sciences
- What is Insider Trading? What You Can Learn from Insider Trading
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Trading Stocks: RSI and Why it’s Useful
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Cassava Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cassava Sciences and related companies with MarketBeat.com's FREE daily email newsletter.